The search for a blood-based biomarker for Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS): from biochemistry to electrophysiology.
Clarke, Krista S P, Kingdon, Caroline C, Hughes, Michael Pycraft et al. · Journal of translational medicine · 2025 · DOI
Quick Summary
This review looked at recent research on finding a simple blood test that could definitively diagnose ME/CFS, which currently takes years and relies on ruling out other diseases. Scientists have found several promising approaches—including measuring immune cell properties, checking how blood cells respond to stress, and detecting metabolic changes—that show they can tell ME/CFS patients apart from healthy people and others with different illnesses. However, these tests need more testing in larger groups and practical refinement before doctors can use them in everyday care.
Why It Matters
ME/CFS patients currently endure years of diagnostic uncertainty and inappropriate treatments due to lack of objective diagnostic criteria; establishing a blood-based biomarker could dramatically reduce time-to-diagnosis, reduce misdiagnosis, and provide scientific validation for a disease often dismissed as psychological. For researchers, these identified biochemical and electrophysiological signatures may illuminate disease mechanisms involving immune dysfunction, metabolic impairment, and ion channel abnormalities, potentially opening therapeutic avenues.
Observed Findings
- Raman spectroscopy of immune cells shows high sensitivity and specificity in separating ME/CFS from non-ME/CFS groups.
- Nano-electronic assays measuring blood electrical impedance during hyperosmotic challenge reveal quantifiable differences in ME/CFS samples.
- Metabolomic assays detect measurable metabolic alterations in ME/CFS patients.
- Mitochondrial dysfunction assessments identify impaired cellular energy metabolism in ME/CFS.
- Evidence suggests acetylcholine receptor and transient receptor potential ion channel dysfunction in ME/CFS, though diagnostic applicability remains unexplored.
Inferred Conclusions
- Multiple disparate biochemical and electrophysiological properties can differentiate ME/CFS patients from controls, suggesting disease involves measurable cellular and immune abnormalities.
- A consistent, stable, and replicable single cytokine profile may be unattainable due to disease heterogeneity, suggesting multiparameter approaches may be necessary.
- Promising blood-based biomarker candidates exist with potential for clinical adoption, but require validation across larger cohorts, disease controls, and practical feasibility assessment before implementation.
Remaining Questions
- Which biomarker candidate or combination of biomarkers demonstrates optimal specificity to ME/CFS versus other post-infectious, autoimmune, or fatigue-related diseases?
- Are these biochemical and electrophysiological differences state-dependent (varying with disease activity/severity) or stable biomarkers suitable for diagnostic confirmation?
- What are the practical, logistical, and cost barriers to implementing these assays in clinical laboratory settings, and which approach offers the best balance of accuracy and adoptability?
- Do these biomarkers reflect disease pathomechanisms or secondary responses to tissue dysfunction, and what do ion channel and mitochondrial findings reveal about underlying disease biology?
What This Study Does Not Prove
This review does not prove that any single biomarker is ready for clinical use—it identifies promising candidates requiring further validation. It does not establish causal mechanisms of ME/CFS, only that measurable differences exist in biological properties. The review does not demonstrate that these biomarkers will be practical, affordable, or accessible in routine clinical settings without additional development.
Topics
Tags
Metadata
- DOI
- 10.1186/s12967-025-06146-6
- PMID
- 39905423
- Review status
- Machine draft
- Evidence level
- Established evidence from major reviews, guidelines, or evidence maps
- Last updated
- 7 April 2026